HUTCHMED climbs after China approves ORPATHYS for gastric cancer treatment
03/07/2026 05:38
BUZZ-HUTCHMED climbs after China approves ORPATHYS for gastric cancer treatment ** Shares of HUTCHMED (China) 0013.HK climb 4.7% to HK$18.42, their highest level since June 3
** Stock set for a fourth consecutive session of gains, if current momentum holds
** The pharmaceuticals products maker says China's National Medical Products Administration has granted conditional approval for new drug application for ORPATHYS for the treatment of gastric cancer patients with MET amplification who have failed at least two prior systemic treatments
** ORPATHYS is under clinical development for multiple tumour types, including lung and gastric cancers as a single treatment and in combination with other medicines, HUTCHMED says
** YTD, stock down 13.5%, Hang Seng Biotech Index .HSBIO down 3.5%
(Reporting by Donny Kwok)
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation